In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Japan To Enlarge Domestic Market Share With New Indications

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly Japan KK plans to increase sales in Japan by seeking new indications for its existing pipeline of drugs. The subsidiary of U.S.-based Eli Lilly, the company began the program by filing for Japanese approval of Gemzar (gemcitabine), a non-small cell lung cancer medicine, for treating biliary tract cancer, and its Cialis (tadalafil) erectile dysfunction drug for treating pulmonary hypertension. The firm says seven of the 13 drugs it has in development are new applications for already-approved products. All of the planning is to reach a goal of moving into the ranks of the top 15 pharmaceuticals in the country by 2025, up from its current 23rd place. (Click here for more - a subscription may be required



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts